PA-Gemox regimen
Showing 1 - 25 of >10,000
Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Guangzhou (pegaspargase, Gemcitabine, Oxaliplatin)
Recruiting
- Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
- pegaspargase
- +5 more
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021
Intrahepatic Cholangiocarcinoma Trial in Hangzhou (Tislelizumab combined with GEMOX (GOT) regimen)
Not yet recruiting
- Intrahepatic Cholangiocarcinoma
- Tislelizumab combined with GEMOX (GOT) regimen
-
Hangzhou, Zhejiang, China1# Banshan East Rd. Zhejiang cancer hospital
Sep 24, 2022
Cholangiocarcinoma Trial in Tianjin (GEMOX Regimen, Lenvatinib, Toripalimab)
Recruiting
- Cholangiocarcinoma
- GEMOX Regimen
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Jan 28, 2022
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System Trial (Tislelizumab)
Not yet recruiting
- Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
- (no location specified)
Sep 6, 2021
Lymphoma, Large B-Cell, Diffuse, Tumors by Histologic Type Trial in China (penpulimab, lenalidomide, Rituximab, Gemcitabine,
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- Neoplasms by Histologic Type
- penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
-
Hefei, Anhui, China
- +3 more
Mar 3, 2022
Tuberculosis, Rifampicin Resistant Tuberculosis Trial in Worldwide (Pretomanid, Optimized background regimen (OBR) for
Not yet recruiting
- Tuberculosis
- Rifampicin Resistant Tuberculosis
- Pretomanid
- Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB
-
Rio De Janeiro, Brazil
- +6 more
Oct 18, 2022
Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)
Active, not recruiting
- Advanced Primary Liver Cancer
- Advanced Biliary Tract Carcinoma
- SHR-1210
- +3 more
-
Zhengzhou, Henan, China
- +1 more
Apr 26, 2022
Unresectable Gallbladder Cancer Trial in Guangzhou (Carrilizumab plus GEMOX)
Not yet recruiting
- Unresectable Gallbladder Cancer
- Carrilizumab plus GEMOX
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jun 16, 2023
NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)
Not yet recruiting
- NK Cell
- +2 more
- autologous NK cell
-
Hubei, Xiangyang, ChinaEC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023
Glaucoma Trial in United States (Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%)
Active, not recruiting
- Glaucoma
- Rocklatan® (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
-
Mission Hills, California
- +20 more
Jan 6, 2023
![](/image/sponsor/university_of_campania_"luigi_vanvitelli")
Metastatic Colorectal Adenocarcinoma Trial in Italy (Cetuximab, FOLFIRI, FOLFOX regimen)
Recruiting
- Metastatic Colorectal Adenocarcinoma
- Cetuximab
- +3 more
-
Ancona, AN, Italy
- +24 more
Mar 28, 2022
Obesity Trial in Atlanta (PATH Intervention, Control Group, Physical activity tracker)
Not yet recruiting
- Obesity
- PATH Intervention
- +3 more
-
Atlanta, GeorgiaEmory University
Nov 7, 2023
Stress, Psychological, Cognitive Decline Trial (MindWalk Intervention)
Not yet recruiting
- Stress, Psychological
- Cognitive Decline
- MindWalk Intervention
- (no location specified)
Aug 16, 2023
Advanced Biliary Tract Tumors Trial in Zhenjiang (Toripalimab injection combined with GEMOX)
Recruiting
- Advanced Biliary Tract Tumors
- Toripalimab injection combined with GEMOX
-
Zhenjiang, Hangzhou, ChinaHaijun Zhong
Dec 6, 2019
Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Manchester (Atezolizumab, Rituximab, Gemcitabine 1000
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
- Atezolizumab
- +3 more
-
Manchester, United KingdomThe Christie NHS Foundation Trust
Jul 26, 2021
Pleural Infection Trial (Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg, Saline irrigation with 250 mls normal
Not yet recruiting
- Pleural Infection
- Intrapleural fibrinolytic with alteplase 5mg and pulmozyme 5 mg
- Saline irrigation with 250 mls normal saline (over 1 hour)
- (no location specified)
Jun 19, 2023
Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer Trial in Tianjin
Recruiting
- Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Nov 16, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Gemox combimed PD1 antibody)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Gemox combimed PD1 antibody
-
Shanghai, Shanghai, ChinaZhongshan hospital
Jul 7, 2021
Glaucoma Trial in San Francisco (App)
Not yet recruiting
- Glaucoma
- App
-
San Francisco, CaliforniaSan Francisco General Hospital
Sep 13, 2023
Combined Hepatocellular Cholangiocarcinoma Trial (gemcitabine ,oxaliplatin,anlotinib,Sintilimab)
Not yet recruiting
- Combined Hepatocellular Cholangiocarcinoma
- gemcitabine ,oxaliplatin,anlotinib,Sintilimab
- (no location specified)
Sep 10, 2023
Lung Diseases, Interstitial Trial in Tampa (Actigraph CP Insight Watch)
Not yet recruiting
- Lung Diseases, Interstitial
- Actigraph CP Insight Watch
-
Tampa, FloridaUniversity of South Florida/ Tampa General Hospital
May 10, 2023
Diffuse Large B-cell Lymphoma Trial in Worldwide (Obinutuzumab, Glofitamab, Rituxumab)
Recruiting
- Diffuse Large B-cell Lymphoma
- Obinutuzumab
- +5 more
-
Birmingham, Alabama
- +77 more
Jul 25, 2022
